IL154011A0 - Treatment of wounds - Google Patents

Treatment of wounds

Info

Publication number
IL154011A0
IL154011A0 IL15401101A IL15401101A IL154011A0 IL 154011 A0 IL154011 A0 IL 154011A0 IL 15401101 A IL15401101 A IL 15401101A IL 15401101 A IL15401101 A IL 15401101A IL 154011 A0 IL154011 A0 IL 154011A0
Authority
IL
Israel
Prior art keywords
wounds
treatment
Prior art date
Application number
IL15401101A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL154011A0 publication Critical patent/IL154011A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15401101A 2000-08-21 2001-08-16 Treatment of wounds IL154011A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020588.0A GB0020588D0 (en) 2000-08-21 2000-08-21 Treatment of wounds
PCT/IB2001/001470 WO2002015893A2 (en) 2000-08-21 2001-08-16 Treatment of wounds

Publications (1)

Publication Number Publication Date
IL154011A0 true IL154011A0 (en) 2003-07-31

Family

ID=9898022

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15401101A IL154011A0 (en) 2000-08-21 2001-08-16 Treatment of wounds

Country Status (10)

Country Link
EP (1) EP1311252A2 (de)
JP (1) JP2004519425A (de)
KR (1) KR20030097778A (de)
AU (1) AU2001276636A1 (de)
CA (1) CA2415791A1 (de)
GB (1) GB0020588D0 (de)
HU (1) HUP0303029A3 (de)
IL (1) IL154011A0 (de)
WO (1) WO2002015893A2 (de)
ZA (1) ZA200301156B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
TWI339578B (en) 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
GB2459098A (en) * 2008-04-08 2009-10-14 Ethicon Inc Genetic markers of wound development
US20120065165A1 (en) * 2008-10-31 2012-03-15 Arginetix, Inc Compositions and methods of treating endothelial disorders
EP2556820A4 (de) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd Zusammensetzung mit einem pde5-hemmer zur glättung von hautfalten
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2333041A (en) * 1998-01-13 1999-07-14 Johnson & Johnson Medical Ltd Wound Composition
AU1025899A (en) * 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
KR20010093828A (ko) * 1998-12-14 2001-10-29 셀러지 파마세우티칼스, 인크 항문직장 질환 치료용 조성물 및 치료 방법
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2411008C (en) * 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
JP2004511433A (ja) * 2000-06-30 2004-04-15 ファイザー・インク 末梢血管疾患、末梢ニューロパシー、及び自律性ニューロパシーの処置方法
IL154202A0 (en) * 2000-07-31 2003-07-31 Cellegy Pharma Inc Pharmaceutical compositions for treating anorectal disorders

Also Published As

Publication number Publication date
AU2001276636A1 (en) 2002-03-04
GB0020588D0 (en) 2000-10-11
JP2004519425A (ja) 2004-07-02
WO2002015893A3 (en) 2003-03-13
EP1311252A2 (de) 2003-05-21
CA2415791A1 (en) 2002-02-28
WO2002015893A2 (en) 2002-02-28
ZA200301156B (en) 2004-04-16
HUP0303029A3 (en) 2004-11-29
KR20030097778A (ko) 2003-12-31
HUP0303029A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
AU2002342613A8 (en) Treatment for wounds
EP1267798A4 (de) Behandlung von hautschäden mit polyenylphosphatidylcholin
AU7434101A (en) Treatment of bone diseases
GB0020351D0 (en) Treatment of hyperproliferative diseases
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU5464601A (en) Treatment of scale
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU5000001A (en) Treatment of vitiligo
GB0001710D0 (en) Therapeutic treatment
IL150479A0 (en) Treatment of psoriasis
NZ513686A (en) Treatment of trauma
GB2360453B (en) Treatment of skin conditions
GB0020588D0 (en) Treatment of wounds
AU2096002A (en) Therapeutic treatment
GB0014356D0 (en) Treatment of multiple sclerosis
GB2381455B (en) Treatment of burns
EP1303281A4 (de) Verfahren zur behandlung
GB0031321D0 (en) Treatment
GB0014904D0 (en) Methods of treatment
GB0013928D0 (en) Methods of treatment
AUPR008500A0 (en) Treatment of pathogens
EP1284748A4 (de) Behandlung geschägigten bindegewebes
AU2638002A (en) Tissue treatment
AU6191201A (en) Treatment of effluent